Invus Financial Advisors, LLC
- SEC CIK
- 0001802978
- Latest filing
- Aug 14, 2024
Holdings in Q1 2021
Holdings as of Mar 31, 2021, filed May 17, 2021. Long positions only.
- Positions
- 7
- No 13F data for Q4 2020
- Portfolio value
- $436.3M
- No 13F data for Q4 2020
Livermore's 13F data starts with Q1 2021, so this quarter has no previous quarter to compare with and changes are not shown.
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| CPNGCoupang, Inc. | CL A | 4,564,571 | $225.3M | 51.6% | – | – | History |
| RCUSArcus Biosciences, Inc. | COM | 1,842,077 | $51.7M | 11.9% | – | – | History |
| OYSTOyster Point Pharma, Inc. | COM | 2,768,586 | $50.6M | 11.6% | – | – | History |
| NVCRNovoCure Ltd | ORD SHS | 350,884 | $46.4M | 10.6% | – | – | History |
| YEXTYext, Inc. | COM | 2,146,785 | $31.1M | 7.1% | – | – | History |
| ORICOric Pharmaceuticals, Inc. | COM | 1,007,575 | $24.7M | 5.7% | – | – | History |
| UBXUnity Biotechnology, Inc. | COM | 1,094,998 | $6.57M | 1.5% | – | – | History |